Samorodnitsky Sarah, Othus Megan, LeBlanc Michael, Wu Michael C
SWOG Statistics and Data Management Center and Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington.
Clin Cancer Res. 2024 Dec 16;30(24):5535-5539. doi: 10.1158/1078-0432.CCR-24-1282.
Evaluating a novel treatment in a randomized controlled trial requires comparison against existing therapies. If several existing therapies of similar benefit exist, the identification of a single control regimen may be difficult. For this situation, we propose a reverse selection design which, in its simplest form, includes a single experimental treatment arm and two control arms. Rather than carrying both control arms through the entire trial, the control arms are compared at an early interim analysis, ideally while accrual is ongoing. At this time, the worst-performing control arm is dropped and randomization continues to the remaining arms. At the end of the study, we compare the treatment to the remaining control arm. When no head-to-head comparison of the extant therapies is available or feasible, this design requires a smaller sample size than a traditional three-arm design or two sequential trials in which the extant therapies are compared and the better treatment is used in a subsequent trial as the control arm. This is because the final comparison is only between two arms and because the early interim analysis occurs prior to the end of accrual-yet with enough information such that any substantially better control arm will be selected. We evaluate the operating characteristics of a reverse selection design via simulation and show that it reduces the required sample size needed to compare the treatment against the best control, controls type I error, and likely selects the right control arm to use in the final analysis.
在随机对照试验中评估一种新疗法需要与现有疗法进行比较。如果存在几种具有相似疗效的现有疗法,那么确定单一的对照方案可能会很困难。针对这种情况,我们提出了一种反向选择设计,其最简单的形式包括一个实验治疗组和两个对照组。不是让两个对照组都贯穿整个试验,而是在早期中期分析时对对照组进行比较,理想情况下是在入组仍在进行时。此时,表现最差的对照组被剔除,随机化继续在剩余组中进行。在研究结束时,我们将该治疗方法与剩余的对照组进行比较。当无法获得或无法进行现有疗法的直接比较时,与传统的三臂设计或两个序贯试验相比,这种设计所需的样本量更小,在传统的三臂设计或两个序贯试验中,会对现有疗法进行比较,并在后续试验中使用更好的治疗方法作为对照组。这是因为最终的比较仅在两组之间进行,并且早期中期分析是在入组结束之前进行的——但有足够的信息,以便能选择出任何明显更好的对照组。我们通过模拟评估了反向选择设计的操作特性,结果表明它减少了将治疗方法与最佳对照组进行比较所需的样本量,控制了I型错误,并且可能会在最终分析中选择正确的对照组。